- Home
- MRKR vs GIGM Comparison
MRKR vs GIGM Comparison
Compare MRKR & GIGM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MRKR | GIGM |
|---|---|---|
| Founded | 1999 | 1998 |
| Country | United States | Taiwan |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.7M | 15.8M |
| IPO Year | 2010 | 2002 |
Fundamental Metrics
Financial Performance| Metric | MRKR | GIGM |
|---|---|---|
| Price | $1.21 | $1.34 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | ★ 84.0K | 4.9K |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 33.61 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $936.27 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.84 | $1.11 |
| 52 Week High | $2.46 | $1.89 |
Technical Indicators
Market Signals| Indicator | MRKR | GIGM |
|---|---|---|
| Relative Strength Index (RSI) | 44.33 | 38.23 |
| Support Level | $1.10 | $1.32 |
| Resistance Level | $1.36 | $1.53 |
| Average True Range (ATR) | 0.12 | 0.06 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 4.76 | 62.16 |
Price Performance
Historical ComparisonAbout MRKR Marker Therapeutics Inc.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from MAR-T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601), and Off-the-Shelf (OTS) products (MT-401-OTS).
About GIGM GigaMedia Limited
GigaMedia Ltd is a diversified provider of digital entertainment services. The only segment and principal business of the company is digital entertainment service business, that operates a portfolio of digital entertainment products, targeting digital entertainment service users across Asia. The company operates digital entertainment business in Taiwan, Hong Kong and Macau through FunTown. The company generates majority revenue from Taiwan.